218 related articles for article (PubMed ID: 19798122)
1. A modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFbeta signaling for breast cancer therapy.
Hu Z; Robbins JS; Pister A; Zafar MB; Zhang ZW; Gupta J; Lee KJ; Newman K; Yun CO; Guise T; Seth P
Cancer Gene Ther; 2010 Apr; 17(4):235-43. PubMed ID: 19798122
[TBL] [Abstract][Full Text] [Related]
2. Systemic delivery of an oncolytic adenovirus expressing soluble transforming growth factor-β receptor II-Fc fusion protein can inhibit breast cancer bone metastasis in a mouse model.
Hu Z; Zhang Z; Guise T; Seth P
Hum Gene Ther; 2010 Nov; 21(11):1623-9. PubMed ID: 20712434
[TBL] [Abstract][Full Text] [Related]
3. Intravenous administration of adenoviruses targeting transforming growth factor beta signaling inhibits established bone metastases in 4T1 mouse mammary tumor model in an immunocompetent syngeneic host.
Zhang Z; Hu Z; Gupta J; Krimmel JD; Gerseny HM; Berg AF; Robbins JS; Du H; Prabhakar B; Seth P
Cancer Gene Ther; 2012 Sep; 19(9):630-6. PubMed ID: 22744210
[TBL] [Abstract][Full Text] [Related]
4. Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-beta receptor II and human immunoglobulin Fc for breast cancer therapy.
Seth P; Wang ZG; Pister A; Zafar MB; Kim S; Guise T; Wakefield L
Hum Gene Ther; 2006 Nov; 17(11):1152-60. PubMed ID: 17032151
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic adenovirus expressing soluble TGFβ receptor II-Fc-mediated inhibition of established bone metastases: a safe and effective systemic therapeutic approach for breast cancer.
Hu Z; Gerseny H; Zhang Z; Chen YJ; Berg A; Zhang Z; Stock S; Seth P
Mol Ther; 2011 Sep; 19(9):1609-18. PubMed ID: 21712815
[TBL] [Abstract][Full Text] [Related]
6. Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-β inhibits established bone metastasis in a prostate cancer mouse model.
Hu Z; Gupta J; Zhang Z; Gerseny H; Berg A; Chen YJ; Zhang Z; Du H; Brendler CB; Xiao X; Pienta KJ; Guise T; Lee C; Stern PH; Stock S; Seth P
Hum Gene Ther; 2012 Aug; 23(8):871-82. PubMed ID: 22551458
[TBL] [Abstract][Full Text] [Related]
7. Ad5/48 hexon oncolytic virus expressing sTGFβRIIFc produces reduced hepatic and systemic toxicities and inhibits prostate cancer bone metastases.
Xu W; Zhang Z; Yang Y; Hu Z; Wang CH; Morgan M; Wu Y; Hutten R; Xiao X; Stock S; Guise T; Prabhakar BS; Brendler C; Seth P
Mol Ther; 2014 Aug; 22(8):1504-1517. PubMed ID: 24791939
[TBL] [Abstract][Full Text] [Related]
8. An oncolytic adenovirus expressing soluble transforming growth factor-beta type II receptor for targeting breast cancer: in vitro evaluation.
Wang ZG; Zhao W; Ramachandra M; Seth P
Mol Cancer Ther; 2006 Feb; 5(2):367-73. PubMed ID: 16505111
[TBL] [Abstract][Full Text] [Related]
9. LyP-1-Modified Oncolytic Adenoviruses Targeting Transforming Growth Factor β Inhibit Tumor Growth and Metastases and Augment Immune Checkpoint Inhibitor Therapy in Breast Cancer Mouse Models.
Xu W; Yang Y; Hu Z; Head M; Mangold KA; Sullivan M; Wang E; Saha P; Gulukota K; Helseth DL; Guise T; Prabhkar BS; Kaul K; Schreiber H; Seth P
Hum Gene Ther; 2020 Aug; 31(15-16):863-880. PubMed ID: 32394753
[TBL] [Abstract][Full Text] [Related]
10. An Oncolytic Adenovirus Targeting Transforming Growth Factor β Inhibits Protumorigenic Signals and Produces Immune Activation: A Novel Approach to Enhance Anti-PD-1 and Anti-CTLA-4 Therapy.
Yang Y; Xu W; Peng D; Wang H; Zhang X; Wang H; Xiao F; Zhu Y; Ji Y; Gulukota K; Helseth DL; Mangold KA; Sullivan M; Kaul K; Wang E; Prabhakar BS; Li J; Wu X; Wang L; Seth P
Hum Gene Ther; 2019 Sep; 30(9):1117-1132. PubMed ID: 31126191
[TBL] [Abstract][Full Text] [Related]
11. Telomerase-specific replication-selective virotherapy for human cancer.
Kawashima T; Kagawa S; Kobayashi N; Shirakiya Y; Umeoka T; Teraishi F; Taki M; Kyo S; Tanaka N; Fujiwara T
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):285-92. PubMed ID: 14734481
[TBL] [Abstract][Full Text] [Related]
12. A novel oncolytic adenovirus expressing Escherichia coli cytosine deaminase exhibits potent antitumor effect on human solid tumors.
Zhang J; Wei F; Wang H; Li H; Qiu W; Ren P; Chen X; Huang Q
Cancer Biother Radiopharm; 2010 Aug; 25(4):487-95. PubMed ID: 20735209
[TBL] [Abstract][Full Text] [Related]
13. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer.
Wirth T; Zender L; Schulte B; Mundt B; Plentz R; Rudolph KL; Manns M; Kubicka S; Kühnel F
Cancer Res; 2003 Jun; 63(12):3181-8. PubMed ID: 12810646
[TBL] [Abstract][Full Text] [Related]
14. Potent anti-tumor activity of telomerase-dependent and HSV-TK armed oncolytic adenovirus for non-small cell lung cancer in vitro and in vivo.
Zhang JF; Wei F; Wang HP; Li HM; Qiu W; Ren PK; Chen XF; Huang Q
J Exp Clin Cancer Res; 2010 May; 29(1):52. PubMed ID: 20487549
[TBL] [Abstract][Full Text] [Related]
15. Systemic Delivery of an Oncolytic Adenovirus Expressing Decorin for the Treatment of Breast Cancer Bone Metastases.
Yang Y; Xu W; Neill T; Hu Z; Wang CH; Xiao X; Stock SR; Guise T; Yun CO; Brendler CB; Iozzo RV; Seth P
Hum Gene Ther; 2015 Dec; 26(12):813-25. PubMed ID: 26467629
[TBL] [Abstract][Full Text] [Related]
16. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
Wang H; Wei F; Li H; Ji X; Li S; Chen X
Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
[TBL] [Abstract][Full Text] [Related]
17. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
[TBL] [Abstract][Full Text] [Related]
18. Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner.
Kim E; Kim JH; Shin HY; Lee H; Yang JM; Kim J; Sohn JH; Kim H; Yun CO
Hum Gene Ther; 2003 Oct; 14(15):1415-28. PubMed ID: 14577922
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy of an hTERT promoter-driven oncolytic adenovirus that expresses apoptin in gastric carcinoma.
Liu L; Wu W; Zhu G; Liu L; Guan G; Li X; Jin N; Chi B
Int J Mol Med; 2012 Oct; 30(4):747-54. PubMed ID: 22842823
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
Watanabe T; Hioki M; Fujiwara T; Nishizaki M; Kagawa S; Taki M; Kishimoto H; Endo Y; Urata Y; Tanaka N; Fujiwara T
Exp Cell Res; 2006 Feb; 312(3):256-65. PubMed ID: 16356494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
